title: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.
abstract: People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.
  
  
  
  To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.
  
  
  
  We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.
  
  
  
  We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.
  
  
  
  We used standard Cochrane methodological procedures. For meta-analyses, we subgrouped studies by vaccine type.
  
  
  
  For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.Compared with control, the vaccine group had a lower likelihood of developing community-acquired pneumonia (CAP) (odds ratio (OR) 0.62, 95% confidence interval (CI) 0.43 to 0.89; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 21 (95% CI 15 to 74). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all-cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types - 23-valent PPV versus 7-valent PCV - and reported no differences for CAP, all-cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV-23.
  
  
  
  Injectable polyvalent pneumococcal vaccination provides significant protection against community-acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate-quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.
authors.affiliation: School of Medicine, University of Tasmania, MSP, 17 Liverpool Street, PO Box 23, Hobart, Tasmania, Australia, 7001.
authors.forename: Julia Ae
authors.initials: JA
authors.lastname: Walters
authors.affiliation: School of Medicine, University of Tasmania, Hobart, Australia.
authors.forename: Joanne Ngie Qing
authors.initials: JN
authors.lastname: Tang
authors.affiliation: Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand.
authors.forename: Phillippa
authors.initials: P
authors.lastname: Poole
authors.affiliation: School of Medicine, University of Tasmania, Hobart, Australia.
authors.forename: Richard
authors.initials: R
authors.lastname: Wood-Baker
mesh_terms: D000368:Aged; D002423:Cause of Death; D017714:Community-Acquired Infections / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000401:mortality / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D022242:Pneumococcal Vaccines